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Abstract
Background: Progression of pancreatic ductal adenocarcinoma (PDAC) is largely the result of genetic and/or
epigenetic alterations in the transforming growth factor-beta (TGF-b)/Smad signalling pathway, eventually resulting
in loss of TGF-b-mediated growth arrest and an increase in cellular migration, invasion, and metastasis. These
cellular responses to TGF-b are mediated solely or partially through the canonical Smad signalling pathway which
commences with activation of receptor-regulated Smads (R-Smads) Smad2 and Smad3 by the TGF-b type I
receptor. However, little is known on the relative contribution of each R-Smad, the possible existence of functional
antagonism, or the crosstalk with other signalling pathways in the control of TGF-b1-induced growth inhibition
and cell migration. Using genetic and pharmacologic approaches we have inhibited in PDAC cells endogenous
Smad2 and Smad3, as well as a potential regulator, the small GTPase Rac1, and have analysed the consequences
for TGF-b1-mediated growth inhibition and cell migration (chemokinesis).
Results: SiRNA-mediated silencing of Smad3 in the TGF-b responsive PDAC cell line PANC-1 reduced TGF-b1-
induced growth inhibition but increased the migratory response, while silencing of Smad2 enhanced growth
inhibition but decreased chemokinesis. Interestingly, siRNA-mediated silencing of the small GTPase Rac1, or ectopic
expression of a dominant-negative Rac1 mutant largely mimicked the effect of Smad2 silencing on both TGF-b1-
induced growth inhibition, via upregulation of the cdk inhibitor p21
WAF1, and cell migration. Inhibition of Rac1
activation reduced both TGF-b1-induction of a Smad2-specific transcriptional reporter and Smad2 C-terminal
phosphorylation in PDAC cells while Smad3-specific transcriptional activity and Smad3 C-terminal phosphorylation
appeared increased. Disruption of autocrine TGF-b signalling in PANC-1 cells rendered cells less susceptible to the
growth-suppressive effect of Rac1 inhibition, suggesting that the decrease in “basal” proliferation upon Rac1
inhibition was caused by potentiation of autocrine TGF-b growth inhibition.
Conclusions: In malignant cells with a functional TGF-b signalling pathway Rac1 antagonizes the TGF-b1 growth
inhibitory response and enhances cell migration by antagonistically regulating Smad2 and Smad3 activation. This
study reveals that Rac1 is prooncogenic in that it can alter TGF-b signalling at the R-Smad level from a tumour-
suppressive towards a tumour-promoting outcome. Hence, Rac1 might represent a viable target for therapeutic
intervention to inhibit PDAC progression.
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TGF-b and its signalling effectors regulate many aspects
of tumour cell biology, such as growth arrest, and cell
motility the latter of which is important for the meta-
static dissemination of tumour cells from their primary
location to lymph or blood vessels [1,2]. TGF-b’s cellular
activities are mediated by specific receptor complexes
that are assembled upon ligand binding and comprise
the TGF-b type II receptor (TbRII) and TGF-b type I
receptor (TbRI/ALK5). The activated ligand-receptor
complex typically activates the Smad signalling pathway.
The canonical Smad signalling cascade is initiated by C-
terminal phosphorylation of receptor-regulated Smad
transcription factors (R-Smads) Smad2 and/or Smad3 by
activated ALK5 [3]. This allows R-Smad binding to
Smad4 and translocation of the complex to the nucleus
where it can recruit transcriptional coactivators or core-
pressors to Smad binding elements (SBEs) in the pro-
moters of TGF-b target genes [1,2]. The TGF-b
signalling effectors are also key players of tumour cell
behaviour and are often deregulated in cancer cells
[2,4]. For instance, human pancreatic ductal adenocarci-
noma (PDAC) is characterized besides the common K-
Ras mutations (representing an early event in PDAC
tumourigenesis) by both TGF-boverexpression and
mutational inactivation of the tumour suppressor
Smad4/DPC4, the latter being a relatively late event.
Recent studies in mice have shown that blockade of
TGF-b/Smad signalling and activated Ras signalling
cooperate to promote PDAC progression [5,6]. The cru-
cial role of the Smad pathway in PDAC formation was
also highlighted in orthotopic xenotransplantation
experiments with TGF-b responsive PANC-1 cells, by
which we demonstrated that Smad signalling through a
kinase-active version of ALK5 suppressed primary
tumour growth, but enhanced metastatic progression
[7]. A recent study in breast cancer cells has revealed
that TGF-b signalling was activated transiently and
locally and caused a switch from cohesive movement to
single cell motility and promoted haematogenous metas-
tasis [8].
Smad2/3 and Smad4 are direct mediators of TGF-b
signalling and there is now ample evidence to suggest
that Smad2 and Smad3 have distinct and non-overlap-
ping roles in TGF-b signalling and that these differ in
epithelial cells and fibroblasts [reviewed in Ref. [9]].
However, relatively few studies on the roles of Smad2
and Smad3 in TGF-b signalling have been performed
in human epithelial cells from which most cancers
arise. Moreover, it remained a mystery why TGF-b can
induce different functions, such as growth arrest and
epithelial-to-mesenchymal transition (EMT), in the
same cell lines, even though both play opposing roles
in tumourigenesis [9]. The mechanisms for the selec-
tive activation of Smad2 versus Smad3 are largely
unknown but can principally occur at the level of the
TbRs, nuclear import and export, protein turnover,
and/or at the transcriptional level. Alternatively,
Smad2 versus Smad3 responses may be selected by
post-translational modifications such as differential
phosphorylation at the TbR complex [9]. It is possible
that the availability of other factors such as co-repres-
sors and co-activators determine which response is
mediated by Smad3 and Smad2. Since strategies for
therapeutic targeting of the TGF-b signalling pathway
are being pursued, revealing the identity of factors that
modulate the relative activation of Smad2 or Smad3 in
the TGF-b response may provide target(s) for more
effective strategies for cancer therapy.
Rac1 belongs to the Rho family of small GTPases and
has been implicated in the organization of the actin
cytoskeleton, the formation of lamellopodia and focal
adhesions, and in endocytic vesicle trafficking and recep-
tor endocytosis. Rac1 can also drive cell proliferation and
protect cells from apoptosis through its ability to activate
extracellular signal-regulated kinases (ERKs), phosphati-
dylinositol-3 kinase (PI3-K), and the transcription factor
NFB [reviewed in Ref. [10]]. Activated Rac1 acts syner-
gistically with ligand-activated epidermal growth factor-
receptor (EGF-R) to stimulate pancreatic tumour cell
proliferation through cyclin D1 upregulation [11]. Rac1
has a critical role in cell migration, and in the invasive,
and metastatic behavior of cancer cells [12-14]. More-
over, Rac1 function is required for oncogenic K-Ras
tumourigenesis and proliferation [15]. Activation of Rac1
is accompanied by its rapid translocation from the cyto-
sol to the cell membrane, where it exerts part of its
effects as an essential subunit of the reactive oxygen spe-
cies (ROS)-producing enzyme NAD(P)H oxidase [16]. In
PDAC dysregulated expression of Rac1 was observed in
the tumour cell compartment [17], along with high activ-
ity of Vav1, a guanine exchange factor (GEF), which exhi-
bits a particularly strong guanine exchange activity for
Rac1 [11]. Also TGF-b and Rac1 signalling exert antago-
nistic roles in tumour cell proliferation but share com-
mon nuclear targets such as cyclin D1 and p21
WAF1
[18,19]. Initial evidence for a role of Rac1 in TGF-b sig-
nalling came from transcriptional reporter gene assays
with dominant negative (dn) and constitutively active
(ca) mutants [20] and this was followed by the demon-
stration that Rac1 is involved in TGF-b-induced EMT
[12]. We have shown earlier that Rac1 is rapidly activated
following stimulation of PDAC cells with TGF-b1a n d
that dn inhibition of Rac1 activity blunted both TGF-b1-
induced p38 MAPK activation and expression of the
small leucine-rich proteoglycan biglycan [21].
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xenotransplantation experiments that Smad signalling
through a kinase-active version of ALK5 suppressed pri-
mary tumour growth and enhanced metastatic progres-
sion [7]. However, the design of this study did not
permit to test why Smad signalling exerted opposite
effects on both responses and whether each response
may be mediated predominantly or exclusively by only
one of the two R-Smads. In this study we therefore
asked whether growth inhibition and cell migration (as
in vitro correlates of tumour growth and metastasis) are
controlled differentially by Smad2 and Smad3 and
whether Rac1 impacts on differential activation of both
R-Smads by TGF-b1. For this purpose, we utilized the
well characterized PDAC cell lines PANC-1 and COLO
357 which have retained a functional TGF-b/Smad path-
way [4,22-24]. Using RNA interference to specifically
deplete cells of the expression of the two R-Smads, we
found that TGF-b1-induced growth inhibition was
dependent on Smad3 (confirming earlier observations in
PANC-1 cells [25]) while the migratory response to
TGF-b1 was positively controlled by Smad2. We went
on to show that Rac1 modulates TGF-b1-signalling in
PDAC cells by suppressing and promoting, respectively,
TGF-b1-induced activation of Smad3 and Smad2, even-
tually resulting in protection of PDAC cells from exces-
sive growth inhibition by TGF-b1 and in enhanced cell
migration (chemokinesis).
Results
Differential control of TGF-b1-induced growth inhibition,
cell migration, and migration-associated gene expression
by Smad3 and Smad2
Using RNA interference to selectively deplete Smad2
and Smad3, a previous study demonstrated that sensitiv-
ity to TGF-b growth-inhibitory signalling (as measured
by cell counting and flow cytometry analyses) was
dependent on the endogenous ratio of Smad2 and
Smad3 in various cell lines including PANC-1 cells [25].
To confirm that this mechanism also operated in the
PANC-1 cells used in our study and to verify functional-
ity of Smad2 and Smad3 small interfering (si) RNAs, we
transfected PANC-1 cells with these siRNAs and subse-
quently measured the growth response to a 24-h treat-
ment with TGF-b1u s i n g[
3H]-thymidine incorporation
(Additional file 1 Figure S1A). In keeping with the idea
that in cells of epithelial origin TGF-b1m e d i a t e si t s
inhibitory effect on cell growth predominantly through
Smad3 [9,25], silencing of Smad3 diminished the inhibi-
tory growth response (Additional file 1 Figure S1A).
Notably, however, in cells with silenced Smad2 the
growth suppressive effect of TGF-b1 on DNA synthesis
was strongly enhanced in a similar fashion (Additional
file 1 Figure S1A). Specificity and selectivity of the
siRNAs for the respective Smads was further confirmed
in immunoblot analysis (Additional file 1 Figure S1A).
As predicted, depletion of the total Smads also
decreased the levels of the respective phospho-Smads
(p-Smads) expressed constitutively (Additional file 1 Fig-
ure S1B) and after stimulation with exogenous TGF-b1
(not shown). Also of interest, the knockdown of Smad2
alone translated into higher expression of the cyclin-
dependent kinase inhibitor p21
WAF1 as shown previously
[25] (Additional file 1 Figure S1A), suggesting that
Smad2 normally acts to suppress p21
WAF1. These data
show that TGF-b1-mediated antiproliferative signals in
PANC-1 cells rely on a Smad3-, but not Smad2-, depen-
dent pathway and that the degree of TGF-b1-induced
growth inhibition can be enhanced by increasing the
endogenous ratio of Smad3 to Smad2.
The relative roles played by Smad2 and Smad3 in the
control of basal and TGF-b1-induced cell motility (che-
mokinesis) in PDAC cells have not yet been uncovered.
To do this, we transfected cells with siRNAs to Smads 2
and 3 as described above and analysed the cell’sm i g r a -
tory response to TGF-b1 with a novel real-time-based
cell migration assay (xCELLigence DP system). As seen
in Figure 1A, PANC-1 cell migration showed an early (5-
6 h) increase which reflected the high spontaneous
migratory activity of these cells and which was largely
independent of exogenously added TGF-b1 stimulation.
This initial rise was followed by a more pronounced and
long-lasting increase in migration which was sensitive to
recombinant TGF-b1 and which peaked between 40 and
50 hrs (Figure 1A). PANC-1 cells (Figure 1A) and COLO
357 cells (Additional file 2 Figure S2B) transfected with
Smad2 siRNA exhibited a basal and exogenous TGF-b1-
triggered migratory activity that was clearly lower than
that of mock-transfected cells (not shown) or cells that
received a matched negative control siRNA. In contrast,
under the same conditions the basal and TGF-b1-
induced motility of Smad3 siRNA transfected cells
exceeded that of the respective controls (Figure 1A). The
finding that Smad3 inhibition failed to impair TGF-b1-
induced chemokinesis was independently confirmed in
COLO 357 cells with a pharmacologic Smad3 inhibitor
(SIS3, [26]) that has been shown not to cross-inhibit
Smad2 (Additional file 2 Figure S2A). These data show
that TGF-b1-mediated promigratory signals in PDAC
cells rely on a Smad2-, but not Smad3-, dependent path-
way and that the intensity of TGF-b1-induced motility
can be modulated by changing the endogenous ratio of
Smad3 to Smad2. To test whether the differential and
antagonistic regulation by Smad2 and Smad3 was also
reflected at the level of individual genes functionally
implicated in the control of TGF-b1-regulated cell migra-
tion/invasion, we analysed the response of the MMP2
and BGN genes (encoding matrix metalloprotease-2 and
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knockdown of Smad3 suppressed, while knockdown of
Smad2 potentiated the TGF-b1-induction of both MMP2
and BGN (Figure 1B).
Specific depletion of Rac1 expression enhances growth
inhibition induced by exogenous TGF-b1
Previous studies from our group have shown that the
small GTPase Rac1 mediated the adhesion-dependency
of TGF-b1-induced gene expression in PDAC cells [21].
To explore potential crosstalk of Rac1 with TGF-b1
antiproliferative signalling, we transfected PANC-1 cells
with siRNA to Rac1 and assessed the effect on basal and
exogenous TGF-b1-stimulated growth inhibition by
[
3H]-thymidine incorporation (Figure 2A, upper panel)
and direct cell counting (Figure 2A, lower panel). As
expected from its cell cycle activating function in other
carcinoma cells, Rac1 depletion attenuated basal growth
of cells cultured in normal growth medium (Figure 2A).
Interestingly, however, in the same cells growth inhibi-
tion induced by exogenous TGF-b1 was clearly
enhanced relative to unstimulated controls (indicated by
the values below the bars in Figure 2). As shown by
immunoblotting, the Rac1 siRNA, but not the irrelevant
control, specifically diminished the level of both total
Rac1 protein (Figure 2B, upper panel) and prevented the
formation of active (GTP-bound) Rac1 in response to
TGF-b1 stimulation (Figure 2B, lower panel). Similar
data with respect to TGF-b1-induced growth inhibition
were obtained for COLO 357 cells [Additional file 3 Fig-
ure S3]. These data show that depletion of Rac1
mimicks the effect of depletion of Smad2 on TGF-b1-
mediated growth inhibition and led us to conclude that
Rac1 antagonizes this cellular function of TGF-b1i n
responsive PDAC cells.
Specific inhibition of Rac1 activity potentiates growth
inhibition induced by exogenous TGF-b1
To scrutinize the role of Rac1 for pancreatic tumour cell
proliferation and to evaluate whether the GTPase function
of Rac1 was required for antagonizing TGF-b1-induced
growth inhibition, we employed previously characterized
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Figure 1 Differential regulation of TGF-b1-induced cell migration and gene expression by Smad2 and Smad3 as revealed by siRNA-
mediated knockdown experiments. PANC-1 cells were transfected twice with siRNAs to Smads 2 and 3, or matched control siRNA, as
described in the Method section and analysed for the cell’s migratory response to TGF-b1 in a real-time cell migration (RTCA) assay (A) and for
regulation of the migration-associated TGF-b1 target genes MMP2 and BGN (B). (A) The relative number of cells that have migrated over the
indicated time period (abcissa) through the pores of the transwells and changed the impedance is given as cell index (ordinata). Data represent
the mean ± s.d. of a representative experiment chosen from a series of three independent experiments. Data are significant because of the large
number of independently measured time points (B) PANC-1 cells were transfected with transfection agent alone (-), control siRNA, or siRNAs
against Smad3 or Smad2 (parallel samples from the experiment shown in A). Seventy-two hours after the first round of transfection cells were
stimulated with TGF-b1 for 24 h and subjected to qPCR analysis for MMP2 and BGN. Data represent the mean ± standard deviation from
triplicate wells after normalization with b-actin and TBP. One out of three experiments is shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Ungefroren et al. Molecular Cancer 2011, 10:67
http://www.molecular-cancer.com/content/10/1/67
Page 4 of 16PANC-1 clones stably expressing dn Rac1 (Rac1-N17)
from a retroviral vector [21]. Several individual clones
were found to have reduced basal growth and to respond
to TGF-b1 with more pronounced growth inhibition when
compared to empty vector controls (Figure 3A) or wild
type cells (not shown) supporting our findings on siRNA-
mediated suppression of RAC1. To exclude the possibility
that enhanced apoptosis rather than growth inhibition
accounted for lower cell numbers or reduced thymidine
incorporation, we measured cell viability in cultures of
PANC-1-dnRac1 stable clones and DNA fragmentation on
PANC-1 cells transiently transfected with dn Rac1, or
GADD45b as control (including both floating and adher-
ent cells). Cell viability as assessed by trypanblue exclusion
was low (< 5%) and was not significantly different between
control and dn Rac1 expressing cells or between untreated
and TGF-b-treated cells (data not shown). The observa-
tion that dn Rac1 lacked a proapoptotic effect was con-
f i r m e db yaq u a n t i t a t i v eD NA fragmentation assay
(Additional file 4 Figure S4). In contrast, ectopic expres-
sion of GADD45b, a Smad3-dependent TGF-b target gene
[27] that can mediate TGF-b-induced apoptosis through
p38 activation [28] (Additional file 4 Figure S4) sensitized
PANC-1 cells to TGF-b1-induced DNA fragmentation.
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Figure 2 Specific inhibition of Rac1 expression mimics the effect of Smad2 knockdown on basal proliferation and enhances growth
inhibition induced by exogenous TGF-b1. (A) PANC-1 cells were transfected with transfection agent alone (-), or with different amounts (as
indicated) of either irrelevant control (Co) or Rac1-specific (Rac1) siRNAs for 3 h. After another 48 h in normal growth medium in the absence or
presence of TGF-b1 cells were either counted (lower panel) or subjected to [
3H]-thymidine incorporation assay (upper panel). The percentage of
TGF-b1-induced growth inhibition relative to the respective untreated control is indicated below the bars. Data represent the mean ±
standard deviation from six wells (thymidine incorporation) or 3 wells (cell numbers) processed in parallel. Shown is a representative
experiment each from three independent experiments. Asterisks, p < 0.001. (B) A fraction of the cells from (A) were subjected to immunoblot (IB)
analysis for Rac1 and b-actin as loading control (upper panel), or were stimulated with TGF-b1 for 15 min and subjected to immunoprecipitation
(IP) of active Rac1 (lower panel). The active Rac1 was subsequently detected by immunoblotting (IB) with a Rac1 antibody. The same antibody
was used with equal amounts of total cellular protein from the original samples to visualize total levels of Rac1.
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pressed proliferation rather than increasing apoptosis in
both control and TGF-b1-treated cells. Next we investi-
gated how Rac1 interacts with the cell cycle machinery to
inhibit the TGF-b1 effect. A central mediator of TGF-b1-
induced growth inhibition in PDAC is the cyclin-depen-
dent kinase inhibitor p21
WAF1 [ 4 , 2 9 - 3 1 ] .N o t a b l y ,i n3 / 3
PANC-1-dnRac1 clones analysed, basal and TGF-b1-
induced levels of p21
WAF1 protein were clearly higher than
in the wild type and vector controls as demonstrated by
immunoblotting (Figure 3B), matching results from the
Smad2 depletion experiments (Additional file 1 Figure
S1A). Overall, these results indicate that inhibition of Rac1
GTPase activity, too, mimicked the effect of Smad2 knock-
down on TGF-b1-dependent proliferation inhibition. We
further conclude that in TGF-b1-responsive PDAC cells
Rac1 activity promotes proliferation by partially antagoniz-
ing TGF-b1-mediated cytostasis via suppression of
p21
WAF1 expression.
Inhibition of RAC1 mimicks the effect of Smad2 silencing
on basal and TGF-b1-induced cell motility
As shown above, siRNA-mediated knockdown experi-
ments in PANC-1 cells suggested that Smad2 positively
regulated TGF-b1-induced cell migration. To explore
whether Rac1, too, promotes TGF-b1-induced motility,
we transfected PANC-1 cells with Rac1 siRNA and
assessed the effect on basal and TGF-b1-stimulated cell
migration. Like Smad2 silencing, RAC1 silencing sup-
pressed both basal and TGF-b1-induced cell migration
but was more potent than Smad2 in this respect (Figure
4A). To confirm these results we, again, employed
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Figure 3 Inhibition of Rac1 activity potentiates TGF-b1-induced growth inhibition and expression of p21
WAF1.( A )P A N C - 1c e l l sw e r e
retrovirally transduced in a stable fashion with dn Rac1 (N17 mutation) and several individual clones tested for their susceptibility to TGF-b1-
mediated growth inhibition by [
3H]-thymidine incorporation assay (left graph) and direct cell counting (right graph). Data represent the mean
± standard deviation from six wells (thymidine incorporation) and 3 wells (cell numbers) processed in parallel. Shown is a
representative experiment each from three independent experiments. Asterisks, p < 0.001. (B) Immunoblot analysis of p21
WAF1 expression in
three individual PANC-1-dn Rac1 clones and control cells stimulated or not with TGF-b1 for 24 h. b-actin was used as a loading control.
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clones utilized for assessment of growth inhibition
above) and subjected them to real-time cellular migra-
tion (RTCA) assay. As expected, ectopic expression of
dn Rac1, too, reduced basal migration and rendered the
cells refractory to TGF-b1-stimulated cell motility when
compared to empty vector and wild type controls (data
not shown). Similar results in RTCA assays were
obtained with both PANC-1 (data not shown) and
COLO 357 cells (Figure 4B) treated with the chemical
Rac1 inhibitor NSC23766. Taken together, the data
clearly show that in PDAC cells basal migratory activity
as well as the migratory response to TGF-b1 stimulation
are strictly Rac1-dependent.
Rac1 inhibition decreased TGF-b1/Smad2-dependent
transcriptional activation but increased TGF-b1/Smad3-
dependent transcriptional activation
Data presented so far indicate that depletion of Smad2
and inhibition of Rac1 in PANC-1 cells potentiated
B
A control siRNA 
control siRNA + TGF-E1
Rac1 siRNA 
Rac1 siRNA + TGF-E1
control 
control + TGF-E1
NSC23766 
NSC23766 + TGF-E1
Figure 4 Inhibition of Rac1 expression or activity mimics the effect of Smad2 silencing on basal and TGF-b1-induced cell motility. (A)
SiRNA-mediated silencing of Rac1 suppresses basal and TGF-b1-induced cell migration. PANC-1 cells were transfected twice with siRNAs to Rac1,
or matched control siRNA, as described in the Method section and analysed for the cell’s migratory response to TGF-b1 in RTCA cell migration
assay. (B) Pharmacologic inhibition of Rac1 inhibits basal and TGF-b1-induced cell migration of PDAC cells. COLO 357 cells (60,000/well) were
pretreated, or not, with 100 μM of the chemical Rac1 inhibitor NSC23766 for 1 h prior to analysis in the RTCA assay which was carried out in the
presence or absence of 100 μM NSC23766. Data in (A) and (B) represent the mean ± standard deviation of four wells processed in parallel. Data
are significant because of the large number of independently measured time points. Shown is a representative experiment chosen from a series
of three independent experiments.
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b1-induced cell motility, while depletion of Smad3 had
the reciprocal outcome. This suggested a functional link
in that Rac1 promotes activation of Smad2 while inhibit-
ing activation of Smad3. To test this prediction more
directly, we analysed in reporter gene assays how Rac1
would impact on Smad2 (and Smad3)-specific transcrip-
tional activities, employing the reporter plasmids pAR3-
luc (Smad2-dependent) and pCAGA-luc (Smad3-depen-
dent). PANC-1 cells were transiently cotransfected with
dn Rac1 and either pAR3-luc (+FAST-1) or pCAGA-luc
and reporter gene activity was measured after 24 h of
TGF-b1 stimulation. Notably, basal and exogenous
TGF-b1-induced luciferase activity from pAR3-luc was
suppressed by cotransfection of dn Rac1 relative to
empty vector-transfected cells (Figure 5A, upper panel),
while that from pCAGA-luc was enhanced albeit moder-
ately (Figure 5A, lower panel). To verify whether chan-
ging the ratio of Smad2 and Smad3 would similarly
affect transcriptional activation of pAR3-luc and
pCAGA-luc by TGF-b1 we depeleted PANC-1 cells of
the two R-Smads by siRNA transfection prior to TGF-
b1 stimulation of reporter gene activity. As expected,
depletion of Smad2 abrogated TGF-b1-induced tran-
scriptional activity of pAR3-luc (Figure 5B, upper panel)
but, notably, enhanced TGF-b1-induced activity of
pCAGA-luc (Figure 5B, lower panel). In contrast, deple-
tion of Smad3 as well as combined depletion of both
Smad2 and Smad3 virtually abrogated pCAGA-luc activ-
ity (Figure 5B, lower panel), confirming the Smad3
dependency of the TGF-b1 effect on this reporter.
These results are in favor of the idea that Rac1 differen-
tially controls Smad2 and Smad3 activation and provide
a molecular correlate to the effect of Rac1 on TGF-b1-
controlled growth suppression.
Inhibition of RAC1 abrogates TGF-b1-mediated
phosphorylation of Smad2 but enhances that of Smad3
The results presented above provided evidence that
Rac1 may directly control the activation of both R-
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Figure 5 Dn Rac1 abrogates Smad2-specific transcription but enhances Smad3-specifc transcription. (A) PANC-1 cells were cotransfected
with the Smad2-specific reporter plasmid pAR3-luc (+ FAST-1), or pCAGA-luc, and dn Rac1, or empty vector as indicated. 24 h after the start of
transfection cells were stimulated with TGF-b1 for another 24 h and subjected to lysis. Firefly luciferase activity was measured and
normalized for Renilla luciferase activity. (B) As in (A) except that cells were transfected with either control siRNA, or Smad2, or Smad3 siRNAs (as
indicated) instead of empty or dn Rac1 plasmid DNAs, as outlined in detail in the Method section. Twenty-four hours after the second round of
transfection cells were stimulated for another 24 h with TGF-b1 followed by lysis and dual luciferase measurements. Shown are data from one
representative experiment (out of at least three performed in total), representing the normalized mean ± standard deviation of 6
wells processed in parallel. **, p < 0.01; ***, p < 0.001.
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sized that Rac1 alters the activation state of Smad2 and
Smad3 by modifying their phosphorylation on serine
residues located at the C-terminus (Smad2: Ser465/467,
Smad3: Ser423/425). To test this assumption, we first
analysed whether dn Rac1 inhibition can alter TGF-b1-
mediated activation of Smad2. Notably, TGF-b1s t i m u -
lated (and unstimulated) p-Smad2 was severely reduced
in dn Rac1 expressing PANC-1 clones (Figure 6, upper
panel: two representative clones are shown). In order to
rule out clonal artefacts, we transiently co-transfected
PANC-1 cells with FLAG-tagged Smad2 along with
either HA-tagged FRNK or MYC-tagged dn Rac1 and
evaluated levels of p-Smad2 following TGF-b1s t i m u l a -
tion. As seen in the stable transfectants, dn Rac1 but
not FRNK, a kinase-deficient mutant and endogenous
inhibitor of p125
FAK [32], abolished phosphorylation of
Smad2 [data not shown] and thus attest to the Rac1-
dependency of TGF-b1-induced Smad2 activation in
PANC-1 cells. Inhibition of TGF-b1-induced p-Smad2
was also seen in COLO 357 cells following Rac1 inhibi-
tion with NSC23766 (Additional file 5 Figure S5). Since
Rac1 inhibition enhanced TGF-b1-mediated growth
inhibition (see Figures 2 and 3) and Smad3-dependent
transcriptional activity (see Figure 5), we evaluated
whether inhibition of Rac1 activity in PANC-1 cells
would also affect Smad3 activation by the TbRI/ALK5
kinase. Interestingly, stable expression of dn Rac1 was
associated with a slight increase rather than a decrease
in p-Smad3 levels in 3 individual clones compared to
wild type and empty vector controls (Figure 6, lower
panel). These data show that Rac1 differentially controls
the activation of Smad2 and Smad3 through
phosphorylation at the C-terminus in a way that corre-
sponds well with the differential functional outcomes of
direct inhibition of both R-Smads. This further supports
our hypothesis that Rac1 promotes Smad2-mediated
TGF-b1 responses, e. g. chemokinesis, while suppressing
Smad3-dependent responses, like growth inhibition.
The growth-inhibitory effect afforded by Rac1 inhibition
and the Smad2 activating function of constitutively active
Rac1 are reduced upon disruption of autocrine TGF-b
signalling
As seen in Figure 2, 3, and 4, Rac1 inhibition by both
siRNA transfection and dn interference lowered prolif-
eration and cell migration not only in TGF-b1-stimu-
lated but also in the absence of exogenous TGF-b1,
suggesting that both growth and motility are partially
controlled in a TGF-b1-independent manner. However,
the observation that PANC-1 cells secrete biologically
active TGF-b1 in vitro [33] may mean that cells could
inhibit their growth and stimulate their migration in an
autocrine fashion, and, consequently, that Rac1 “pro-
tects” cells from autocrine growth inhibition but at the
same time ensures autocrine stimulation of cell migra-
tion. We investigated this possibility for the growth pro-
m o t i n gr o l eo fR a c 1 .T od ot h i sw eu s e dP P 1 ,as m a l l
molecule compound that has recently been shown in
mammary epithelial cells [34] and in PANC-1 cells [35]
to potently inhibit the kinase activity of TbRI/ALK5, to
suppress TGF-b1-induced phosphorylation of Smad2
and Smad3 and EMT [35]. In addition, we have demon-
strated that PP1 dose-dependently relieved the growth
suppressive effect of TGF-b1 in a Src-unrelated fashion
[35]. To determine whether the autocrine TGF-b
growth-inhibitory loop was subject to regulation by
Rac1, we evaluated the effect of Rac1 depletion on pro-
liferative activity upon silenced autocrine TGF-b signal-
ling under PP1 treatment. As shown in Figure 7A, PP1
increased the DNA synthesis (as a measure of the prolif-
erative activity) in PANC-1 cells and, importantly,
decreased the growth-inhibitory effect of Rac1 siRNA
when compared to vehicle controls.
We further reasoned that if TGF-b autostimulation
was permanently operating in cultures of PANC-1 cells
(as suggested by clearly detectable levels of p-Smad2/3
in unstimulated cells, see Additional file 1 Figure S1B,
and Figure 6) then ectopic expression of a ca mutant of
Rac1 (Q61L) should be able to stimulate p-Smad2 even
in the absence of exogenous TGF-b1. This assumption
was tested in transient cotransfection/immunoprecipita-
tion assays. Here, ca Rac1 was able to enhance the
amount of p-Smad2 over empty vector control samples
in the absence of added TGF-b1 and PP1 (Figure 7B,
lane 3), but was unable to do so in the presence of PP1
(Figure 7B, lane 7). Together, these data strongly suggest
dnRac1 vector #1 #2
p-Smad2
t-Smad2
0 40 100 0 40 100 0 40 100 TGF-E1 [min]
dnRac1
vector wt #1 dnRac1 #2 dnRac1 #3  dnRac1
p-Smad3
t-Smad3
TGF-E1++ + + + - -- --
Figure 6 Inhibition of Rac1 differentially affects TGF-b1-
mediated C-terminal domain phosphorylation of Smad2 and
Smad3. PANC-1-dn Rac1 cells used in Fig. 3 were analysed along
with wild type (wt) cells and empty vector (vector)-transduced
control cells by immunoblotting for their ability to phosphorylate
Smad2 (p-Smad2, upper panel) and Smad3 (p-Smad3, lower panel)
in response to TGF-b1 stimulation (Smad3: 1 h, Smad2: as indicated
in the figure). Total Smad levels (t-Smad) were detected as loading
controls.
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Page 9 of 16that Rac1 modulates Smad signalling in response to
both exogenous and autocrine TGF-b(s) signalling.
Discussion
In this study we initially presented evidence that TGF-
b1-induced growth inhibition and cell migration in
PDAC cells were differentially and selectively controlled
by Smad3 and Smad2, respectively. Knockdown of
Smad3 but not Smad2 relieved TGF-b1-induced growth
inhibition, indicating that this response was Smad3-
dependent, an observation made previously in various
other cell types including PANC-1 cells [9,36,25]. In
contrast, knockdown of Smad2 decreased the TGF-b1-
driven motility of PDAC cells revealing cell migration
(or more precisely chemokinesis) to be a Smad2-specific
r e s p o n s e .T h i si si nl i n ew i t ht h ed e m o n s t r a t i o no fa
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Figure 7 Blocking autocrine TGF-b signalling renders PANC-1 cells resistant towards the growth-suppressive effect of Rac1 inhibition.
(A) PANC-1 cells were transfected with Rac1 or control (Co) siRNA as outlined in the legend to figure 1. Fourty-eight hours later cells were
treated with PP1 (10 μM) or vehicle for 24 h and subjected to [
3H]-thymidine incorporation assay. Data represent the mean ± standard deviation
from six wells processed in parallel. **, p < 0.01; ***, p < 0.001; n.s., not significant. (B) PANC-1 cells were transiently cotransfected with FLAG-
tagged Smad2 and a MYC-tagged version of ca Rac1 (Q61L) as indicated over the figure. 24 h after transfection cells were stimulated or not
with TGF-b1 for 1 h in the absence or presence of 10 μM PP1. Following lysis and anti-FLAG and anti-MYC IPs, samples were analysed by
sequential immunoblotting for phospho- (p-) and total (t-) Smad2 as well as Rac1.
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tion during wound healing [37]. We went on to describe
first-time observations, namely that the effects of Smad2
depletion on TGF-b1-mediated growth inhibition and
cell migration were largely mimicked by inhibition of
Rac1 expression (via siRNA knockdown) or activity (via
ectopic expression of a dn Rac1 mutant), or pharmaco-
logic inhibition (via NSC23766), together suggesting a
functional link between both proteins. We subsequently
confirmed this assumption by showing that Rac1 inhibi-
tion abrogated TGF-b1-induced Smad2-specific C-term-
inal phosphorylation and transcriptional activity but
increased TGF-b1-mediated p21
WAF1 expression.
Another interesting and novel observation of this study
was the mutual amplification of effects such that knock-
down of Smad2 or inhibition of Rac1 (without direct
modulation of Smad3) enhanced growth inhibition,
Smad3-specific transcriptional activity, and C-terminal
phosphorylation of Smad3, while knockdown of Smad3
(without direct modulation of Smad2) enhanced both
Smad2-specific responses such as cellular migration
(this study) and Smad2 phosphorylation by TGF-b [25].
This suggested functional antagonism between the two
R-Smads and that the ratio of Smad3 to Smad2 deter-
mines the ultimate outcome of the TGF-b response as
demonstrated previously for TGF-b-induced growth
inhibition in PANC-1 cells [25].
The decreases in basal proliferation of PANC-1 and
COLO 357 cells following Rac1 inhibition may be lar-
gely due to disruption of promitogenic growth factor
signalling. PDAC cells, e.g. PANC-1 cells, are well
known to autostimulate their proliferation in culture via
secretion of EGF. Consequently, both the tyrosine kinase
inhibitor tyrphostin AG1478 and the ERK inhibitor
U0126 dramatically inhibited PANC-1 cell proliferation
(H. U., unpublished data). The intimate relationship
between the TGF-b and EGF-R pathways in growth reg-
ulation of carcinoma cells is also evident from studies
showing that TGF-b1 can suppress PDAC cell prolifera-
tion by repressing EGF-R-induced ERK activation [38]
and that EGF signalling, in turn, is permissive for regu-
lation of gene expression and growth suppression by
TGF-b1 [39]. Previous observations of TGF-b1 secretion
in vitro [33], and suppression of “basal” p-Smad2/3
levels and BGN mRNA upon ALK5 inhibition [21,23,40]
clearly suggested that PANC-1 cells may also exhibit
autocrine TGF-b growth inhibition. Previous studies in
breast cancer cells have shown that cell cycle progres-
sion/inhibition is subject to regulation by autocrine
TGF-b [41,42]. In order to block autocrine TGF-b sig-
nalling we used PP1, which in PDAC cells effectively
blunted growth inhibition induced by exogenously
added and autocrine TGF-b’s (Figure 7). Importantly, in
the presence of PP1 siRNA-mediated Rac1 depletion
resulted in much less growth inhibition than in control
transfected cells with functional TGF-b/Smad signalling.
Hence, reduced DNA synthesis in cells with low Rac1
activity (and not exposed to exogenous TGF-b1) may, at
least in part, be explained by increased susceptibility to
autocrine growth inhibition by TGF-b’s. Similar observa-
tions (an increase in growth suppression even in the
absence of exogenous TGF-b)w e r em a d eb yK i ma n d
coworkers [25] upon depletion of Smad2 in PANC-1
cells and these authors showed that this response disap-
peared in the presence of neutralizing anti-TGF-b anti-
body. These results perfectly match our data on the
sensitization to autocrine TGF-b responses obtained
through pharmacologic inhibition of ALK5 and further
support our hypothesis of Rac1-mediated control of
Smad2 activation.
Interestingly, the decrease in basal and TGF-b1-
induced growth upon dn Rac1 expression was accompa-
nied by a respective increase in expression of p21
WAF1.
In line with these results, Rac1 activity was both neces-
sary and sufficient for suppression of p21
WAF1 in pros-
tate cancer cells [19].
As discussed above, the decreases in basal prolifera-
tion following Rac1 inhibition may involve both disrup-
tion of promitogenic growth factor signalling and loss of
protection from autocrine TGF-b-mediated growth inhi-
bition as a consequence of the shift from p-Smad2 to p-
Smad3 signalling. Similarly, as the inhibition of Rac1
was much more effective in suppressing basal and TGF-
b1-induced cell migration than was the inhibition of
Smad2 expression (compare Figures 2 and 5), Rac1 is
likely to control cell motility, too, in part in an autocrine
TGF-b-dependent (and TGF-b-independent) fashion.
There is now ample evidence that Smad2 and Smad3
have distinct functional and non-overlapping roles in
TGF-b signalling [9] implying that intracellular factors
which control the relative activation state of Smad2 ver-
sus Smad3 signalling have a central role in determining
the final outcome of the TGF-b response. Here, we
showed that PANC-1 cells responded to inhibition of
Rac1 with a pronounced decrease in TGF-b1-mediated
p-Smad2 and a slight increase in p-Smad3. In agreement
with these data, dn Rac1 expression not only decreased
Smad2-specific transcriptional activity (on pAR3-luc)
but enhanced general Smad3-specific transcriptional
activity (on pCAGA-luc). Moreover, dn Rac1 also
increased p21
WAF1 protein expression which is in line
with data showing that p21
WAF1 was transcriptionally
induced by TGF-b in a Smad3-dependent manner in
pancreatic, hepatic and skin cells [30,18,43]. However,
TGF-b-induced transcription of another reporter gene
(p3TP-lux) in HepG2 cells was effectively inhibited by
Rac1-N17 expression [20] which might be explained by
the fact that this plasmid is partially responsive to non-
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functional antagonism observed, a likely explanation is
that Smad2 and Smad3 compete with each other either
i) for binding to TbRI/ALK5, ii) capture of Smad4 in
the cytoplasm, or iii) recruitment of transcriptional core-
pressors to SBEs in the nucleus, the latter of which is
normally performed by Smad2 [1]. As a consequence, a
reduction in Smad2 expression or activation would
increase the ability of Smad4 to bind Smad3 on the
SBEs of target gene promoters. In agreement with this
possibility are experiments in PANC-1 cells, in which
direct silencing of Smad2 via siRNA transfection did not
only augment TGF-b1-induced Smad3 phosphorylation
[25], p21
WAF1 expression and growth inhibition (Addi-
tional file 1 Figure S1 and Ref. [25]), but also poten-
tiated TGF-b1-induction of Smad3-regulated genes such
as MMP2 and BGN (see Figure 1). Indirect evidence
that the endogenous ratio of Smad2 and Smad3 deter-
mines the quality of the TGF-b response was observed
in Hep3B cells, in which the expression of Smad3-
Smad4-dependent TGF-b target genes was further
enhanced after selective knockdown of SMAD2 [44],
and in mouse keratinocytes, in which Smad2 loss led to
a significant increase in Smad3-Smad4 binding to the
promoter of the transcription factor Snail, Snail upregu-
lation, and EMT [45]. Indirect evidence that competition
can be mutual comes from a study with Smad2 and
Smad3-deficient fibroblasts, in which activation of the
pAR3-luc reporter, though strongly suppressed in
Smad2-deficient fibroblasts, was enhanced in Smad3-
null cells [46]. Regarding the intracellular site of compe-
tition (see above) our data favour Smad recruitment or
binding to ALK5 since dn Rac1 stimulated a shift from
p-Smad2 to p-Smad3.
As mentioned above, Rac1 has been found to be over-
expressed in PDAC [17] along with high activity of
Vav1 [11]. Hyperactive Rac1 could therefore increase
basal growth through its (TGF-b/Smad-independent)
growth promoting effect and, at the same time, protect
tumour cells, which have not yet accumulated inactivat-
ing mutations in the TGF-b pathway, from exaggerated
growth restraints by TGF-b. More specifically, Rac1 aids
cancer cells to more efficiently antagonize TGF-b1/
Smad3-mediated growth inhibition via its ability to pro-
mote Smad2 activation. Interestingly, hyperactive Ras
(present in both PANC-1 and COLO 357 cells) has
been shown, like Rac1, to suppress ALK5-mediated
Smad3 phosphorylation and growth inhibition [47].
Oncogenic Ras-induced transformation can lead to the
production of superoxide through one or more pathways
involving NAD(P)H oxidase(s)/Nox1 and Rac1 [48]. In
this way Rac1 may act as a mediator of Ras-induced cell
cycle progression independent of MAPK and JNK and
may contribute to the unchecked proliferation of Ras-
transformed cells [48]. Notably, preliminary data from
our laboratory indicate that Rac1 acts through ROS and
NAD(P)H oxidase to promote Smad2 phosphorylation
(H. U., unpublished observation).
The mechanism described here for Rac1 differs from
the previously described ones in that it reciprocally tar-
gets Smad2 and Smad3 at the posttranscriptional level.
It is widely appreciated that Rac1 acts in a prooncogenic
fashion during later stages of tumour progression by
promoting migration, invasion, and metastasis [13,14].
In addition to fundamental differences in the mechan-
ism of Smad2 and Smad3 activation by TGF-b1, at least
in PDAC cells, our study reveals that Rac1 may drive
tumourigenesis in carcinoma cells with a still intact
TGF-b/Smad pathway by favouring resistance to TGF-
b1-mediated growth inhibition and by increasing TGF-
b1-induced cell migration at the R-Smad epigenetic
level.
Conclusions
In malignant PDAC cells with a functional TGF-b sig-
nalling pathway Rac1 antagonizes the TGF-b1 cytostatic
response and enhances cell migration by differentially
regulating Smad2 and Smad3 activation. Thus, Rac1
m a yb ee m p l o y e db yc e l l sa sas w i t c ht of i n e - t u n e
Smad2 versus Smad3-dependent TGF-b1r e s p o n s e s .
This study reveals that Rac1 is prooncogenic in that it
can alter TGF-b signalling at the R-Smad level from a
tumour-suppressive towards a tumour-promoting
outcome.
Methods
Antibodies and reagents
TGF-b1 was purchased from R&D Systems (Wiesbaden,
Germany). The antibodies and their suppliers were:
Rac1, p21
WAF1: BD Transduction Laboratories (Heidel-
berg, Germany); phospho-Smad2 (Ser465/467), phos-
pho-Smad3 (Ser423/425)/Smad1(Ser463/465), HSP90,
MYC-Tag (clone 9B11): Cell Signalling Technology
(Heidelberg, Germany); Smad2: Zymed (Berlin, Ger-
many); FAK (C-20), Smad2/3 (E-20): Santa Cruz Bio-
technology (Heidelberg, Germany); b-actin, FLAG (M2):
Sigma (Deisenhofen, Germany); HA (12CA5): Roche
Diagnostics (Mannheim, Germany), active Rac1: New-
East Biosciences (Malvern, USA). PP1 analog, the
Smad3 inhibitor SIS3, and the Rac1 inhibitor NSC23766
were purchased from Calbiochem/Merck (Darmstadt,
Germany). Pharmacological inhibitors were added to
cells 30 min before the addition of TGF-b1w h i c hw a s
used at 5 ng/ml for both PANC-1 and COLO 357 cells.
Cell lines and cell culture
Maintenance of the human PDAC cell lines PANC-1
and COLO 357 was described earlier [23]. PANC-1 cells
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cultured in the presence of 2.5 μg/ml puromycin
(Sigma).
RNA isolation and RT-PCR analysis
Total RNA from PANC-1 cells was isolated with peq-
GOLD RNAPure (Peqlab, Erlangen, Germany) and
reverse transcribed using Superscript II Reverse Tran-
scriptase (Invitrogen). The primer sequences for BGN,
b-actin, MMP-2, and TATA box binding protein (TBP)
were given earlier [7,23]. The mRNA expression was
quantified by quantitative real-time RT-PCR (qPCR) on
an I-Cycler (Bio-Rad, München, Germany) with I-Cycler
software (Bio-Rad). SYBR green was used for detection
of amplification products. All values for BGN and
MMP-2 mRNA concentrations were normalized to
those for b-actin and TBP-specific transcripts in the
same sample to account for small differences in cDNA
input.
Construction of vectors and retroviral infection
The construction of a retroviral vector (pBABEpuro) for
human dn Rac1 (T17N mutation) [21] and of pcDNA3-
based expression vectors for FLAG-tagged Smad2 and
GADD45b [40] was described previously. A cDNA
insert of a MYC-tagged version of dn Rac1 was released
from the pRK5-MYC vector and subcloned in pcDNA3.
Transient transfections of expression vectors and siRNAs
and reporter gene assays
For transient transfections followed by immunoprecipi-
tation (IP), PANC-1 cells were seeded at a density of 2
×1 0
4 cells/cm
2 in 6-cm plates on day 1, and on day 2
were co-transfected serum-free with Lipofectamine Plus
(Invitrogen) according to the manufacturer’s instructions
with FLAG-tagged Smad2 in combination with either
empty pcDNA3 vector, HA-tagged FRNK, MYC-tagged
dn Rac1 (T17N), or MYC-tagged ca Rac1 (Q61L) as
indicated in the legend to Figure 7. Following removal
of the transfection solution and a recovery period of 24
h in normal growth medium, cells were stimulated with
TGF-b1 for 1 h. The transfected cells were then lysed in
IP buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerolphosphate, 1 mM
Na3VO4,1μg/ml leupeptin, 1 mM PMSF) and pro-
cessed for anti-FLAG, anti-HA, and anti-MYC immuno-
precipitation and immunoblotting (see below). SiRNAs
specific for Rac1 (ON-TARGETplus SMARTpool, a
mixture of four prevalidated siRNAs) and matched
negative control (non-target control SMARTpool) were
purchased from Thermo Scientific Dharmacon (Epsom,
UK), while prevalidated siRNAs to Smad2 and Smad3 as
well as matched control were from Qiagen (Hilden,
Germany) [33]. Rac1, Smad2/3, and negative control
siRNAs were transfected twice on two consecutive days
with either Lipofectamine 2000 or Lipofectamine RNAi-
Max (PANC-1) and HiperFect (COLO 357) (all from
Invitrogen) according to the supplier’s recommenda-
tions. For reporter gene assays, cells were seeded in 96-
well plates and were co-transfected on the next day
serum-free with either Lipofectamine Plus or Lipofecta-
mine 2000 (Invitrogen) with various cDNAs (in
pcDNA3) at an equal molar ratio together with dn Rac1
and either pAR3-luc+FAST-1, or pCAGA-luc, along
with the Renilla luciferase encoding vector pRL-TK
(Promega, Mannheim, Germany). Each well received the
same total amount of DNA (0.2 μg) and empty vector
was added as needed. Following transfection and TGF-
b1 stimulation, luciferase activities were determined
with the Dual Luciferase Assay System (Promega). Pilot
experiments with pCAGA-luc and increasing concentra-
tions (5, 25, and 100 ng/well) of dn Rac1-pcDNA3 DNA
indicated that the effect of dn Rac1 was dose-dependent
(data not shown). In case of combined siRNA/plasmid
DNA transfections PANC-1 cells underwent a first
round of transfection with siRNA alone (on day 1 after
seeding) and Lipofectamine RNAiMax, followed by a
second round with siRNA plus plasmid DNA and Lipo-
f e c t a m i n e2 0 0 0( o nd a y2 ) .I na l lr e p o r t e rg e n ea s s a y s
the data were derived from 6-8 wells processed in paral-
lel and corrected for transfection efficiency with Renilla
luciferase activity.
Immunoprecipitation and immunoblot analysis
Epitope-tagged proteins were immunoprecipitated from
cellular lysates with anti-FLAG, anti-HA, or anti-MYC
antibodies and Protein A Sepharose Fast Flow (Amer-
sham Biosciences, Freiburg, Germany) or protein G Plus
Sepharose (Santa Cruz Biotechnology) according to the
protocol provided by the supplier, and subsequently
analyzed by SDS-PAGE and immunoblotting as
described in detail earlier [23].
Proliferation and apoptosis assays
Cell counting of was performed with Cedex XS cell analy-
sis system (Roche Diagnostics, Mannheim, Germany)
according to the instruction manual. The methyl-[
3H]-thy-
midine incorporation assay was essentially carried out as
described previously [7,23]. Twenty-four hours after tran-
sient transfection with expression plasmids for dn Rac1 or
GADD45b, a JAM DNA fragmentation assay was per-
formed as outlined in detail earlier [49]. Briefly, transfected
PANC-1 cells were trypsinized and reseeded at a density
of 1-2 × 10
4 cells/well into 96-well flat bottom plates,
allowed to adhere overnight and labelled with [
3H]-thymi-
dine (370 KBq/μl) for 4 h. Subsequently, non-incorporated
radioactivity was removed by washing the cells with PBS.
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medium for 24 h, cells were harvested by vacuum aspira-
tion on glass fiber filters. Dried filters were counted into a
liquid scintillation counter (Wallac, Switzerland). The per-
centage of specific DNA fragmentation, indicative of apop-
tosis, was calculated as: % viability = (E/S) × 100, where E
(experimental) is cpm of retained DNA in the presence of
TGF-b1a n dS (spontaneous) is cpm of retained DNA in
the absence of TGF-b1.
Measurement of cell migration
Using the xCELLigence DP device from Roche Diagnos-
tics real-time measurements of cell migration on wild
type or transfected PANC-1 and COLO 357 cells were
performed. 60,000-90,000 cells were seeded per well in
CIM-Plates 16 (Roche Diagnostics). Prior to cell seeding
the underside of the wells was coated with collagen I
(400 μg/ml, Sigma, Deisenhofen, Germany) which was
chosen since it represents the major matrix protein in
PDAC tissue. TGF-b1 (and in some experiments phar-
macologic inhibitors) were added to both lower and
upper wells at the same concentration. The RTCA assay
was performed as detailled by Roche Diagnostics in the
instruction manual. In those experiments in which cells
underwent transfection they were processed to enter the
assay 24-48 hrs after the second round of transfection.
In experiments involving small molecule inhibitors, cells
were pretreated for 1 h before the addition of TGF-b1.
Data acquisition and analysis were performed with the
RTCA software (version 1.2, Roche Diagnostics) over a
period of 48 h.
Statistical analysis
Statistical significance was calculated using the unpaired
student’s t-test. Data were considered significant at p <
0.05. Calculated levels of significance were p <0 . 0 5( * ) ,
p < 0.01 (**), and p < 0.001 (***).
Additional material
Additional file 1: Figure S1. Effect of siRNA-mediated silencing of
Smad2 and Smad3 on TGF-b1-induced growth suppression in PANC-1
cells. [
3H]-thymidine incorporation assay of PANC-1 cells depleted of
Smad2 or Smad3 by siRNA transfection.
Additional file 2: Figure S2. Effect of Smad3 inhibition and Smad2
depletion on TGF-b1-induced chemokinesis in COLO 357 cells as
measured with the RTCA real-time cell migration assay. (Figure S1)
Migratory response of TGF-b1-treated COLO 357 cells in the absence or
presence of a pharmacologic Smad3 inhibitor and (Figure S2) after
siRNA-mediated depletion of Smad2.
Additional file 3: Figure S3. SiRNA-mediated depletion of Rac1
decreases basal proliferation and enhances TGF-b1-induced growth
suppression. Proliferation assay of TGF-b1-treated COLO 357 cells
transiently transfected with Rac1 siRNA.
Additional file 4: Figure S4. Reduced thymidine incorporation by Rac1
suppression is the result of reduced proliferation rather than increased
apoptosis. Apoptosis assay of TGF-b1-treated PANC-1 cells transiently
transfected with dn Rac1.
Additional file 5: Figure S5. Immunoblot analysis of TGF-b1-mediated
phosphorylation of (endogenous) Smad2 in COLO 357 cells in the
absence or presence of the pharmacologic Rac1 inhibitor NSC23766.
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